Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 1Lung Neoplasms 1Carcinoma, Small Cell 1Breast Neoplasms 1

Interventions

Etoposide 31Carboplatin 30atezolizumab 17durvalumab 16Cisplatin 14Topotecan 11PM 01183 11Specimen Handling 9pembrolizumab 8Magnetic Resonance Spectroscopy 7olaparib 5Radiotherapy 5berzosertib 4anlotinib 4Paclitaxel 4Nivolumab 4Irinotecan 4Drug Therapy 4tremelimumab 3toripalimab 3tislelizumab 3Temozolomide 3Radiosurgery 3Injections 3Docetaxel 3Biopsy 3Bevacizumab 3AMG 757 3sacituzumab govitecan 2monalizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × EC regimen × 90 days × Clear all
NCT07625644 2026-06-04

Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer

SystImmune Inc.

Phase 3 Not yet recruiting
550 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡